Array reports updated data for encorafenib/binimetinib/Erbitux in metastatic CRC

Array BioPharma Inc. (NASDAQ:ARRY) reported updated response data for a combination regimen of encorafenib (LGX818), binimetinib (MEK162) and Erbitux cetuximab in the safety lead-in portion of the Phase III BEACON CRC trial to treat BRAF V600E-mutant metastatic colorectal cancer after one or two prior lines

Read the full 456 word article

User Sign In